Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Vaccine ; 41(17): 2824-2828, 2023 04 24.
Artigo em Inglês | MEDLINE | ID: mdl-36997387

RESUMO

INTRODUCTION: Routine vaccination for hepatitis B is recommended at birth, and most infants should be vaccinated within 24 h of life. Historically, vaccination rates have been less than ideal, and routine vaccination has been further complicated by the COVID-19 pandemic, with decreased uptake of many vaccines. This retrospective study assessed hepatitis B vaccination rates at birth before and after the start of the COVID-19 pandemic and explored the factors associated with lower vaccination rates. METHODS: Infants born at a single academic medical center in Charleston, South Carolina from November 1, 2018 through June 30, 2021 were identified. Infants were excluded if they died or received ≥ 7 days of systemic steroid therapy within the first 37 days of life. Maternal and infant baseline characteristics and uptake of the first hepatitis B vaccine during hospital admission were recorded. RESULTS: A total of 7808 infants were included in the final analysis, with an overall vaccine uptake of 91.6 %. Of the 3880 neonates in the pre-pandemic group, 3583 (92.3 %) were vaccinated, versus 3571 (90.9 %) of 3928 neonates in the pandemic group (rate difference = 1.4 %; 95 % confidence interval -2.8 % to 5.7 %, p = 0.52). Factors independently associated with lower vaccine uptake included being of non-Hispanic white race, born to a married mother, birth weight < 2 kg, and parental refusal of erythromycin eye ointment at birth. CONCLUSION: The COVID-19 pandemic did not significantly affect the uptake of inpatient neonatal hepatitis B vaccination. Several patient-specific factors were associated with suboptimal vaccination rates in this population.


Assuntos
COVID-19 , Hepatite B , Recém-Nascido , Lactente , Feminino , Humanos , Vacinas contra Hepatite B , Estudos Retrospectivos , Pandemias/prevenção & controle , COVID-19/prevenção & controle , Vacinação , Hepatite B/epidemiologia , Hepatite B/prevenção & controle , Mães
2.
Adv Neonatal Care ; 21(3): E65-E72, 2021 06 01.
Artigo em Inglês | MEDLINE | ID: mdl-33427753

RESUMO

BACKGROUND: Standardized parenteral nutrition (PN) formulations are used in at-risk neonates to provide nutrition immediately following birth. However, evidence for the optimal formulation(s) to maximize growth while reducing the risks of glucose and electrolyte abnormalities is limited. PURPOSE: The purpose of this study was to compare the rates of hypernatremia and hyperglycemia with 2 weight-based standardized PN formulations versus one standard PN in low birth-weight preterm neonates. METHODS: This was a single-center observational study of infants less than 1800 g birth weight and less than 37 weeks' gestation who received standardized PN in the first 48 hours of life. Patients in the weight-based PN group were compared with a historical group of patients receiving single standard PN. Rates of hypernatremia and hyperglycemia were compared by χ2 analysis. RESULTS: There was a nonsignificant (P = .147) reduction in hypernatremia in the weight-based PN group (9 of 87; 10.3%) compared with the single PN group (16 of 89; 18.0%). However, hyperglycemia was significantly more frequent in the weight-based group than in the single PN group (24.1% vs 12.4%, P = .035). IMPLICATIONS FOR PRACTICE: The 2 weight-based PN standardized formulations studied did not significantly decrease the incidence of hypernatremia or hyperglycemia. IMPLICATIONS FOR RESEARCH: Future studies to determine optimal standardized PN to provide early nutrition in high-risk neonates are warranted.


Assuntos
Hiperglicemia , Hipernatremia , Humanos , Hiperglicemia/epidemiologia , Hiperglicemia/prevenção & controle , Hipernatremia/epidemiologia , Hipernatremia/prevenção & controle , Incidência , Lactente , Recém-Nascido , Recém-Nascido Prematuro , Nutrição Parenteral
3.
J Pediatr Pharmacol Ther ; 17(3): 206-10, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23258962
4.
Pharmacotherapy ; 29(8): 997-1001, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19637954

RESUMO

Gabapentin is a gamma-aminobutyric acid analog used for numerous neurologic conditions, including neuropathic pain and epilepsy. We describe a 39-week gestational age, male infant with hypotonicity, functional short gut, and microduplication of chromosome 22 who was treated with gabapentin to control pain and irritability. During his hospitalization, the infant experienced multiple complications including respiratory distress, persistent pulmonary hypertension of the newborn, hypocalcemia, hypoglycemia, hyperbilirubinemia, gastroesophageal reflux, necrotizing enterocolitis, and cholestatic jaundice. Pain associated with related invasive procedures and surgeries was treated with intermittent and scheduled morphine. In addition to postoperative and procedural pain, the infant continued to experience pain and irritability attributed to neurologic impairment, presumably secondary to his chromosomal abnormality. Trials of scheduled lorazepam along with intermittent morphine and phenobarbital were unsuccessful in managing these symptoms. After failure of nonpharmacologic treatment and continued trials of sedatives and analgesics, gabapentin 5 mg/kg at bedtime was started on day of life 98. Improvement in the infant's tone and disposition was noted by numerous health care professionals and the infant's mother. In addition, the infant's pain scores, using the Pain Assessment in Neonates Scale, showed marked improvement. The infant continued to receive gabapentin; the dosage was increased to 10 mg/kg at bedtime after 6 days, then to 5 mg/kg in the morning and 10 mg/kg at bedtime 10 days later. When the infant was 7 months old, his mother requested that gabapentin be discontinued. He was slowly weaned, and the drug was discontinued when he was 11 months old. The infant tolerated gabapentin well except for experiencing nystagmus, which was noted 31 days after starting the drug and resolved after drug discontinuation. Clinicians should be aware of gabapentin as an alternative treatment for pain and irritability in neurologically impaired infants. Further study is needed, however, to verify the drug's safety and efficacy in neonates and infants. Standardized pain scales along with close patient monitoring will help to guide clinicians in dosage titration to optimize therapy.


Assuntos
Aminas/uso terapêutico , Analgésicos/uso terapêutico , Ácidos Cicloexanocarboxílicos/uso terapêutico , Humor Irritável/efeitos dos fármacos , Doenças do Sistema Nervoso/diagnóstico , Dor/tratamento farmacológico , Ácido gama-Aminobutírico/uso terapêutico , Aminas/administração & dosagem , Ácidos Cicloexanocarboxílicos/administração & dosagem , Gabapentina , Humanos , Recém-Nascido , Masculino , Doenças do Sistema Nervoso/genética , Dor/complicações , Ácido gama-Aminobutírico/administração & dosagem
6.
J S C Med Assoc ; 98(3): 145-54, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12125197

RESUMO

As discharge approaches, usually indicated by feeding progression, thermoregulation and other events, it is important for the medical team to develop a plan of action and stick with it, assuming that nothing untoward happens. Experience tells us that families of infants with special needs at discharge cope better and maintain a more positive attitude if plans are clearly defined and followed consistently. A coordinated team approach is also helpful for personnel responsible for arranging equipment, training, and home health services.


Assuntos
Recém-Nascido de Baixo Peso , Planejamento de Assistência ao Paciente , Alta do Paciente , Humanos , Recém-Nascido , Pais/educação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...